Opdivo

Analyzing the monthly immuno-oncology sales data, Leerink said Merck & Co., Inc. (NYSE: MRK)'s Keytruda is picking up speed, but Bristol-Myers Squibb Co (NYSE: BMY)'s Opdivo is flattish. Immuno-Oncology Market On Strong Wicket Analyst Richard Goss noted that Symphony Health sales showed...

Lung and bronchus cancer is the leading cause of cancer deaths in the United States, according to the National Cancer Institute. Lung cancer is of two types, namely non-small cell lung cancer, or NSCLC and small cell lung cancer, or SCLC, with the former more prevalent than the latter. Estimates by...

Shares of Merck & Co., Inc. (NYSE: MRK) are rallying strongly, while Bristol-Myers Squibb Co (NYSE: BMY) is being punished on Wednesday. News Behind The Move The contrasting moves come after Merck announced late Tuesday that the FDA has accepted to review the sBLA for KEYTRUDA, plus...

The ESMO 2016 Oncology Conference took place over the weekend in Copenhagen, Denmark. News out of the conference is making a big splash in the market on Monday. Here’s a look at what you may have missed. Bristol-Myers Squibb Co (NYSE: BMY) shares are down 10.17 percent after the company...

This year’s European Society for Medical Oncology conference was one that Bristol-Myers Squibb Co (NYSE: BMY) shareholders would like to forget. The primary focus for Bristol-Myers was the company’s failed CM-26 trial. Bristol-Myers shares are down 9.4 percent in early Monday...

Merck & Co., Inc. (NYSE: MRK) shares are pushing higher by 1.9 percent on Monday following the company’s encouraging new data on Keytruda. On Sunday, Merck reported that Keytruda reduced patient deaths by 40 percent compared to chemotherapy alone and cut disease progression in half....

After Bristol-Myers Squibb Co (NYSE: BMY) disclosed disappointing study results of its Opdivo, SunTrust has reduced the price target on the company's shares from $68 to $62 on lower EPS estimates for the year 2017 and 2018. However, the firm maintains its Hold rating on the stock. Analyst John...

Seattle Genetics, Inc. (NASDAQ: SGEN) received a ratings bump from Goldman Sachs to Neutral from Sell after the brokerage revised its Adcetris U.S. sales estimates in 1L Hodgkin's lymphoma (HL) "to reflect greater market penetration per physician diligence." "We model 40 percent penetration (vs. 19...

In the past week, Bristol-Myers Squibb Co's (NYSE: BMY) loss has been Merck & Co., Inc.'s (NYSE: MRK) gain. When Bristol-Myers reported back on August 5 that Opdivo did not meet its targets for treatment of advanced non-small cell lung cancer, the stock tanked 16 percent. Merck...

Bristol-Myers Squibb Co (NYSE: BMY) saw its shares crater from near $75 last week to nearly $60 per share after the company reported a major setback for its cancer-treating drug, Opdivo. Bristol-Myers said Opdivo failed to meet a primary endpoint in the treatment of lung cancer during the...

The U.S. stock market posted strong gains on Friday to close out the week in the wake of a better-than-expected nonfarm payrolls number. The Dow and Nasdaq each climbed over 1 percent on the session, while the Nasdaq gained a little less than 1 percent. Stock gainers included Mercadolibre Inc (...

BMO has downgraded Merck & Co., Inc. (NYSE: MRK) shares to Market Perform from Outperform on valuation. "The so called 'TINA' (there is no alternative) effect is not enough for us to remain bullish at these levels; the fundamentals have not improved to justify higher valuations. In fact, we are...

Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies. For Eli Lilly and Co (NYSE: LLY), ASCO will be...

The meat of large-cap pharmaceutical earnings season starts this week. Johnson & Johnson (NYSE: JNJ)’s strong Q1 report last week has Credit Suisse analyst Vamil Divan hopeful that AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly and Co (NYSE: LLY) will be able...